 |
| CLICK HERE TO VIEW CURRENT ISSUE |
 |
| Best of NAMA 2026 |
|
 |
|
LIVESTOCK REPRODUCTION DEVELOPER EMGENISYS COMPLETES OVERSUBSCRIBED FINANCING ROUND
Jul. 28, 2025
Source: EmGenisys news release
Driftwood, TX -- EmGenisys, a pioneering animal health company leveraging artificial intelligence to evaluate embryo health in real-time, today announced the successful close of an oversubscribed $1.5 million seed financing round.
The round was led by Grit Road Partners, with participation from leading agtech venture capital firms Tall Grass Ventures, and Ag Venture Alliance. The capital reflects strong confidence in EmGenisys' mission to empower veterinarians, embryologists, and cattle producers with real-time, objective insights that improve IVF and embryo transfer outcomes--ultimately boosting pregnancy rates and maximizing return on genetic investment.
EmGenisys' flagship product, EmVision, is a machine learning-powered platform that analyzes 30-second videos of embryos recorded using a smartphone mounted to a microscope. The web-based system examines each embryo frame-by-frame, assessing for signs of life and generating an immediate embryo health score. This data helps producers select the most viable embryos for transfer and considerably improve the efficacy of their IVF program.
"Attracting some of the most strategic investors in animal health and genetics gives EmGenisys both the financial and human capital to scale globally," said Dr. Cara Wells, founder and CEO of EmGenisys. "This funding will allow us to advance our AI platform, expand access to our technology, and deliver real impact for beef and dairy producers around the world."
"This financial backing will allow us to continue to develop and improve services which will benefit both novice and experienced embryologists and their clients." said Dr. Russell Killingsworth, Co-founder and Chief Veterinary Officer with over 40 year's experience practicing bovine embryo transfer in the Texas panhandle.
Founded in 2020 by Dr. Cara Wells and Dr. Russell Killingsworth, EmGenisys has already achieved key milestones, including the issuance of 15 U.S. patents, successful pilot studies, and recognition from leading organizations in both ag tech and biotech sectors. Accolades include the BioTools Innovator Award at Boston Biotech Week and the Animal Health Corridor Innovation Award in Kansas City. With this new capital, EmGenisys plans to accelerate commercialization of the technology, expand into additional livestock species, and launch new product offerings aligned with reproductive success and genetic progress.
"We are incredibly excited to partner with EmGenisys. Their innovative, data-driven approach to improving embryo transfer outcomes is a game-changer for livestock producers," said Mike Jung, Managing Partner at Grit Road Partners. "This partnership perfectly aligns with our mission at Grit Road Partners to back cutting-edge AgTech solutions that deliver real, measurable impact for Midwest agriculture."
"EmGenisys is advancing a very exciting innovation in the livestock sector. EmGenisys's team has blended artificial intelligence with advanced livestock reproduction technologies in the way that other's haven't been able to do in the industry," said Wilson Acton, Managing Partner at Tall Grass Ventures. "We are excited to work closely with the EmGenisys team to accelerate and grow their business."
|
|
|
|
|
